SOURCE: CLX Investment Company, Inc.

May 05, 2006 09:00 ET

CLX Investment Company Announces Zonda, Inc. Director of European Sales to Meet with Major Distributors

TEMECULA, CA, -- (MARKET WIRE) -- May 5, 2006 -- CLX Investment Company, Inc. (OTC BB: CLXN) today announced that Pavel Holik, director of European sales for portfolio company Zonda, Inc., has traveled to Europe to meet with major distributors for the HandiLab-C test for chlamydia.

Mr. Holik's itinerary includes meetings with distributors of the HandiLab-C test for countries in Scandinavia, the Benelux, the United Kingdom, and other regions. Ongoing negotiations are expected to produce several additional distribution agreements in the coming weeks that will expand the HandiLab-C's presence into a larger number of countries.

The HandiLab-C is the only over-the-counter chlamydia test that carries the CE mark, signifying that the product complies with the relevant health, safety, environmental protection requirements and can therefore be legally placed on the market in Europe, where it is currently distributed in over 15 countries.

"Face-to-face meetings with Zonda's distribution partners for the Europe market are vital as the company expands its reach on the continent and cements new relationships," stated Tammy D. Dunn, chief executive officer of CLX Investment Company. "Broader distribution translates into increased sales and eventually greater value for Zonda, Inc. in the CLX investment portfolio. The potential new distributors with which Mr. Holik will be meeting during this trip are well established in their respective markets and should achieve fairly rapid penetration for the HandiLab-C in both over-the-counter and professional care applications.

"We are extremely confident in Mr. Holik's ability to work with a diverse group of distribution companies and within a myriad of regulatory frameworks, especially given his extensive experience working under the constraints of worldwide government regulations related to the aviation industry," added Ms. Dunn.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About Zonda, Inc.

Zonda, Inc. (, in which CLX holds a 31% equity interest, specializes in diagnostic tests that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda's product line includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and Group A Strep, tests that detect bacterial and other potential harmful micro-organisms on surfaces, and confirmation tests for a wide variety of bacteria. The HandiLab-C test for chlamydia carries a CE mark for both professional point-of-care and over-the-counter use. The gonorrhea, yeast and Group A Strep tests carry CE marks for professional point-of-care use, and Zonda is seeking similar approvals for over-the-counter sales of these products. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to PCR or DNA testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.

About CLX Investment Company

CLX Investment Company ( holds a 31% equity interest in Zonda, Inc. (, a privately held company that specializes in test products that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Also in the CLX investment portfolio is a 49% interest in eStrategy Solutions, Inc. (, a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. CLX has invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    Email Contact